NovaBay Pharmaceuticals reported a net loss of $1.6 million, or $0.09 per share, in the second quarter of 2018 compared with a net loss of $1.7 million, or $0.11 per share, in 2017’s second quarter.
Net sales decreased from $4.1 million in 2017’s second quarter to $2.8 million in 2018’s second quarter. The company attributed the decrease to a delay “in hiring new sales representatives and increasing managed care coverage for Avenova,” according to a press release.
Sales and marketing expenses were $3 million compared with $3.4 million a year (Read more...)
Uncategorized